![These highlights do not include all the information needed to use ABILIFY ASIMTUFII safely and effectively. See full prescribing information for ABILIFY ASIMTUFII. ABILIFY ASIMTUFII® (aripiprazole) extended-release injectable suspension, for ... These highlights do not include all the information needed to use ABILIFY ASIMTUFII safely and effectively. See full prescribing information for ABILIFY ASIMTUFII. ABILIFY ASIMTUFII® (aripiprazole) extended-release injectable suspension, for ...](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=abilify-15.jpg&id=768341)
These highlights do not include all the information needed to use ABILIFY ASIMTUFII safely and effectively. See full prescribing information for ABILIFY ASIMTUFII. ABILIFY ASIMTUFII® (aripiprazole) extended-release injectable suspension, for ...
![These highlights do not include all the information needed to use ABILIFY safely and effectively. See full prescribing information for ABILIFY. ABILIFY® (aripiprazole) Tablets, for oral use ABILIFY DISCMELT® ( aripiprazole) Orally Disintegrating These highlights do not include all the information needed to use ABILIFY safely and effectively. See full prescribing information for ABILIFY. ABILIFY® (aripiprazole) Tablets, for oral use ABILIFY DISCMELT® ( aripiprazole) Orally Disintegrating](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=abilify-03.jpg&id=677325)
These highlights do not include all the information needed to use ABILIFY safely and effectively. See full prescribing information for ABILIFY. ABILIFY® (aripiprazole) Tablets, for oral use ABILIFY DISCMELT® ( aripiprazole) Orally Disintegrating
What are the negative effects of aripiprazole on teenagers brains? (Permanent and temporary) - Quora
![FDA Approves Otsuka and Lundbeck's ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults FDA Approves Otsuka and Lundbeck's ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults](https://newsroom.lundbeckus.com/content/dam/lundbeck/active/misc/newsroom/images/news-releases/Ari%202-Month%20Approval_V3.png)